Font Size

SCREEN

Profile

Direction

Menu Style

In Brief
  1. ISIRV Journal: IRV Journal impact factor is now 4.4
  2. Abstract submission deadline for RSV2025 has been extended to 15 November.
13th International RSV Symposium (RSV2025)
Return to RSV Webinar Series home page                                                                                                               

 RSV WEBINAR SERIES                                     February 2021

PROGRAMME

 

1 February  Epidemiology and Spectrum of RSV Disease

  3pm (GMT)               Chair: Dr Natasha Halasa, Vanderbilt University Medical Center, USA

VIEW WEBINAR RECORDING

Keynote Presentation:

RSV Epidemiology in a Changing World
Chair of Paediatric Infectious Diseases and Global Health
Centre for Global Health, Usher Institute
The University of Edinburgh, UK
 
(30 min presentation - includes 5 min for Q&A)
 
 
The impact of respiratory syncytial virus (RSV) on mortality and hospitalizations in Hong Kong, 1998-2015
Xiong Qian   |   University of Hong Kong, Hong Kong      (15min)
 

Early life severe respiratory syncytial virus infection increased the risk of asthma later in life Maarten van Wijhe    |   Statens Serum Institut, Denmark     (15min)

 
The Clinical Characteristics, Severity, and Seasonality of RSV Subtypes among Hospitalized Jordanian Children
Ahmad Yanis    |    Vanderbilt University Medical Center, Nashville, USA    (15min)
 
Maternal and family social risk factors for early life respiratory syncytial virus (RSV)-related hospitalizations
Tiffany Fitzpatrick   |   Yale School of Public Health, New Haven, USA   (15min)
 
 

 

8 February  RSV Molecular Biology

 3pm (GMT)                         Chair: Prof Ultan Power, Queens University Belfast, UK

VIEW WEBINAR RECORDING

 
Keynote Presentation:
Insights into the generation and function of defective viral genomes during RSV infection
Prof Carolina Lopez
BJC Investigator / Lopez Lab
Department of Molecular Biology
Washington University School of Medicine in St. Louis, USA
 
(30 min presentation - includes 5 min for Q&A)
 
Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus ON1 and BA9 strains enables rapid evaluation of naturally occurring antibody escape mutants
Martin Ludlow   |  University of Veterinary Medicine Hannover Foundation, Hannover, Germany       (15min)
 
 
Trimerization of the RSV Fusion protein leads to a high energy prefusion state, or why trimerizing is destabilizing RSV F
Johannes Langedijk   |   Janssen Vaccines & Prevention, The Netherlands       (15min) 
 
 
The respiratory syncytial virus attachment glycoprotein is altered when produced in primary human bronchial epithelial cultures, reducing its infectivity for cell lines
Tiffany King   |   The Ohio State University / Nationwide Childrens Hospital, USA         (15min)
 
An unexpected encounter: RSV-NS1 interacts with a member of the mediator complex
Tessa Van Royen   |   VIB-UGent Center for Medical Biotechnology, Ghent University, Belgium     (15min)
 
 

 

15 February  RSV Pathogenesis and Immunity

 3pm (GMT)                            Chair: Dr Lindsay Broadbent, Queens University Belfast, UK

VIEW WEBINAR RECORDING

Keynote Presentation:

An integrated view of susceptibility and resistance to RSV disease
Prof Peter Openshaw
Department of Experimental Medicine
Imperial College London, UK
 
(30 min presentation - includes 5 min for Q&A)
 
Localization of Respiratory Syncytial Virus (RSV) Antigen in Bronchiolar Epithelium
Mark Ackermann   |   LambCure LLC and Oregon State University, USA  (15min)
 
 
Influenza Virus Inhibits RSV Infection via a Two-wave Expression of IFIT Proteins
Michal Mandelboim   |   Sheba Medical Center, Ramat Gan, Israel  (15min)
 
 
Characterizing RSV Immunity on Mucosal Surfaces Following Natural Infection
Peter F. Wright   |   Geisel School of Medicine at Dartmouth, Hanover, USA   (15min)
Presented by co-author  Meave Otieno
 
Immunological impact of age in an experimental RSV challenge model in elderly humans 
Stephanie Ascough   |   Imperial College London, UK    (15min)
 
 

 

22 February  RSV Vaccines and Therapies

 3pm (GMT)                            Chair: Dr Simon B. Drysdale, St George's Hospital, London, UK

VIEW WEBINAR RECORDING

Keynote Presentation:

How RSV Biology Informed COVID-19 Vaccine Development
Dr Barney S. Graham
Deputy Director
Vaccine Research Center
National Institute of Allergy and Infectious Diseases, USA
 
(30 min presentation - includes 5 min for Q&A)
 
 
A Single-cycle Live RSV Vaccine Expressing Prefusion F Protein
Pramila Lamichhane   |   Oklahoma State University, USA      (webinar recording not available at this time)

 
Phase 1/2a Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Seropositive Toddlers Aged 12 -24 Months
Matthew Snape   |   University of Oxford, UK     (15min)
 
 
The Sensitivity of Palivizumab Cost-effectiveness in Mali to Case Fatality Estimates
 Amanda Driscoll   |   University of Maryland, Baltimore, USA    (15min)

 
The Flavonoid Cyanidin Shows Antiviral and Immunomodulatory Properties Against RSV, in Vitro and in Vivo
Carlos Bueno  |   Universidad de Buenos Aires, Argentina     (15min) 

 

 

 

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save